Reach Us +44-1647-403003
Alice Lin-Tsing Yu | OMICS International
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Alice Lin-Tsing Yu

Alice Lin-Tsing Yu
Associate Director
Genomics Research Center
Academia Sinica
Taiwan Tel: +886-2-2789-9930


Dr. Alice is Distinguished Research Fellow and Associate Director, Genomics Research Center, Academia Sinica and Professor of Pediatric (joint appointment), Department of Medicine, National Taiwan University since 2003, 2006 respectively. She is the Committee member for evaluating 2008 Key Government Science and Technology Programs since 2007. Honored for being an principal investigator for many awards and grants. Honored at the S.D. Padres Stadium for launching a new vaccine study for children with neuroblastoma in the year 2000. She has joined many societies like International Society for Stem Cell Research American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology etc.

Research Interest

Dr. Yu has a longstanding interest in translational research, aiming to bridge the gap between laboratory research and clinical medicine. In particular, she has been pursuing therapy targeting specific molecular alterations in cancer from small molecules to biologics. She has led several nationwide cooperative group clinical trials in the USA. As a pioneer in cancer immunotherapy targeting GD2, she has taken an anti-GD2 monoclonal antibody from IND application through phase I, II and III clinical trial which culminated in significant improvement in the outcome of high risk neuroblastoma. She is now developing therapeutic cancer vaccines targeting GD2 with anti-idiotypic antibody for neuroblastoma and melanoma, and glycans such as GloboH and Gb5 with synthetic carbohydrates for the treatment of epithelial cancers including cancers of breast, lung, ovary, pancreas, etc. She has a broad spectrum of research interest ranging from molecular signature of cancer and cancer stem cells, cell cycle regulation, in vitro and in vivo preclinical screening of novel therapeutic agents, design, development and implementation of clinical protocols for immunotherapy and other clinical investigation.

Global Speakers in the subject

Global Experts in the subject